DPT Laboratories acquires Meda Pharmaceuticals New Jersey facility
Will meet the current need for additional cold storage and a larger analytical laboratory
DPT Laboratories, a contract development and manufacturing organisation (CDMO) with a specialised focus on semi-solid and liquid dosage forms, has acquired Meda Pharmaceuticals’ facilities in Lakewood, New Jersey, US.
The acquisition reflects the organisation's recent growth, allowing DPT to expand its footprint in Lakewood by adding two buildings totalling 90,000ft2 of space. The real estate meets DPT’s current need for additional cold storage and a larger state-of-the-art analytical laboratory.
'The Meda Pharmaceuticals space allows us to meet the needs of our clients today and beyond,' said Gene Ciolfi, vice president and general manager, Lakewood site operations. 'We are also in a better position to explore additional opportunities to further our capabilities from development through commercialisation.'
As part of the acquisition, DPT will also absorb Meda Pharmaceuticals’ employees to continue the manufacturing of MUSE, its urethral suppository product.
DPT’s current Lakewood location is one of its established Centres of Excellence. This centre provides state-of-the-art aseptic processing suites and filling equipment for small-volume parenterals, ophthalmic preparations, preservative-free nasal sprays and sterile ointments.